Geron (NASDAQ:GERN) will be releasing its earnings data after the market closes on Thursday, August 1st. Analysts expect Geron to post earnings of ($0.06) per share for the quarter.

Geron (NASDAQ:GERN) last released its earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($0.05) EPS for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.02. Geron had a negative net margin of 3,713.04% and a negative return on equity of 17.53%. The firm had revenue of $0.06 million during the quarter, compared to analyst estimates of $0.23 million. On average, analysts expect Geron to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

GERN traded up $0.02 during trading on Tuesday, reaching $1.20. 12,833 shares of the company’s stock were exchanged, compared to its average volume of 1,698,908. The firm has a fifty day moving average of $1.37. Geron has a fifty-two week low of $0.95 and a fifty-two week high of $6.99. The firm has a market cap of $219.16 million, a price-to-earnings ratio of -7.41 and a beta of 2.68.

A number of analysts have commented on GERN shares. BidaskClub raised shares of DENTSPLY SIRONA from a “buy” rating to a “strong-buy” rating in a report on Thursday, June 13th. Needham & Company LLC reaffirmed a “buy” rating and set a $100.00 target price on shares of LivaNova in a report on Tuesday, April 9th. B. Riley set a $71.00 target price on shares of Brunswick and gave the stock a “buy” rating in a report on Friday, June 28th. Finally, ValuEngine lowered shares of Zumiez from a “hold” rating to a “sell” rating in a report on Tuesday, July 2nd. Two analysts have rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $3.33.

Geron Company Profile

Geron Corporation, a clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for hematologic myeloid malignancies. The company supports the clinical stage development of imetelstat, a telomerase inhibitor for the treatment of hematologic myeloid malignancies.

Featured Story: Gap Up Stocks

Earnings History for Geron (NASDAQ:GERN)

Receive News & Ratings for Geron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Geron and related companies with's FREE daily email newsletter.